New pill shows promise for tough lymphoma cases

NCT ID NCT04993690

First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 24 times

Summary

This study tests an experimental oral drug called LP-168 in adults with B-cell lymphoma that returned or didn't respond to standard treatments. The main goals are to find the safest dose and check if the drug can shrink tumors. About 200 participants will take the drug daily, and researchers will monitor side effects and cancer response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Beijing Cancer Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100142, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Peking University Third Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100089, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Sun Yat-sen University Cancer Center

    RECRUITING

    Guangzhou, Guangdong, 510060, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.